Randomized trial demonstrates KLF2's role in CD8 T cell fate and migration, indicating its significance in infection and cancer.
Introduction Besides acute infection, CX3CR1+ effector-like CD8 T cells also appear in chronic infection and cancer. Whether there is a central transcriptional regulator of the effector fate is unclear. Methods Here, using joint single-cell profiling of the transcriptome and epigenome of chimeric antigen receptor (CAR) T cells, we identified KLF2 as a hub transcription factor in the gene regulatory network of effector-like CAR T cells. Results KLF2 deficiency abolished effector-like differentiation in both CAR T cells and antiviral CD8 T cells. KLF2 deficiency also impaired the differentiation of the stem-like subset. In both chronic viral infection and cancer, KLF2 deficiency impaired CD8 T cell infiltration to non-lymphoid tissues. However, unlike CAR T cells, KLF2-deficient antiviral CD8 T cells showed a greater expansion in the lymphoid tissue. Single-cell transcriptomics analysis revealed that KLF2-deficient CD8 T cells upregulated the transcriptional signature of terminally exhausted T cells and downregulated the signature of effector-like T cells, suggesting a central role of KLF2 in regulating the bifurcation of effector versus terminal exhaustion cell fates. In addition, the TOX-controlled transcriptional program was upregulated in KLF2-deficient CD8 T cells. KLF2 deficiency downregulated multiple genes associated with T cell migration including S1pr1. S1PR1 deficiency impaired the effector-like subset, whereas deficiency of CD69, a negative regulator of S1PR1, increased the effector-like subset. Notably, aging downregulated KLF2 in antigen-specific CD8 T cells, impaired the differentiation of the CX3CR1+ subset, and upregulated the TOX-mediated transcriptional program. Conclusion Thus, our study demonstrates KLF2 as a central regulator of the effector fate and migration of CD8 T cells. Funding Source NIH, CRI, AFAR, V Foundation Topic Categories Immune Response Regulation: Molecular Mechanisms (IRM)
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: